Tag: 100-200

Related Products of 52096-24-9On March 31, 2013, Fokin, S. V.; Kostina, E. T.; Tret’yakov, E. V.; Romanenko, G. V.; Bogomyakov, A. S.; Sagdeev, R. Z.; Ovcharenko, V. I. published an article in Russian Chemical Bulletin. The article was 《Spin transition in the molecular heterospin complex of Cu(hfac)2 with 4,4,5,5-tetramethyl-2-(1-methylpyrazol-5-yl)-4,5-dihydroimidazole-1-oxyl 3-oxide》. The article mentions the following:

The synthesis, structure, and magnetic properties of the products of the reaction for Cu(hfac)2 (hfac is hexafluoroacetylacetonate) with spin-labeled nitronyl nitroxides 4,4,5,5-tetramethyl-2-(1-R-1H-pyrazol-5-yl)-3-imidazoline-1-oxyl 3-oxides L5/R (R = Me, Et, Pr, Bu), viz., binuclear complex [Cu(hfac)2L5/Me]2 and chain polymer complexes [Cu(hfac)2L5/R]n, are described. The polymer heterospin chains are built according to head-to-head (R = Me, Et, Pr, Bu) and head-to-tail (R = Pr, Bu) motifs. [Cu(hfac)2L5/Me]2 was characterized by the ability to reveal the reversible effect of thermally induced spin transition at a temperature ∼75 K (without hysteresis). In the set of heterospin CuII compounds with spin-labeled pyrazoles, this is the earlier unknown example of a mol. complex exhibiting a similar magnetic anomaly. In addition to this study using 1-Butyl-1H-pyrazole, there are many other studies that have used 1-Butyl-1H-pyrazole(cas: 52096-24-9Related Products of 52096-24-9) was used in this study.

1-Butyl-1H-pyrazole(cas: 52096-24-9) belongs to pyrazoles. Pyrazoles and their related multiring analogs are common elements of a wide variety of bioactive compounds. These ring structures are rare in nature. A consequence of this is that they have previously been thought to be poor moieties to include in potential new drugs. Related Products of 52096-24-9

Referemce:
Pyrazole – Wikipedia,
Pyrazoles – an overview | ScienceDirect Topics

HPLC of Formula: 29004-73-7On March 31, 2020, Wu, Yumeng; Tang, Chengrun; Rui, Ruomei; Yang, Liumeng; Ding, Wei; Wang, Jiangyuan; Li, Yiming; Lai, Christopher C.; Wang, Yueping; Luo, Ronghua; Xiao, Weilie; Zhang, Hongbing; Zheng, Yongtang; He, Yanping published an article in Acta Pharmaceutica Sinica B. The article was 《Synthesis and biological evaluation of a series of 2-(((5-akly/aryl-1H-pyrazol-3-yl)methyl)thio)-5-alkyl-6-(cyclohexylmethyl)-pyrimidin-4(3H)-ones as potential HIV-1 inhibitors》. The article mentions the following:

A series of 2-(((5-akly/aryl-1H-pyrazol-3-yl)methyl)thio)-5-alkyl-6-(cyclohexylmethyl)-pyrimidin-4(3H)-ones I [R1 = H, Me, Ph, etc.; R2 = H, Me, Et; X = H, Cl] were synthesized and their anti-HIV-1 activities were evaluated. Most of these compounds were highly active against wild-type (WT) HIV-1 strain (IIIB) with EC50 values in the range of 0.0038-0.4759μmol/L. Among those compounds,I [R1 = 4-hydroxyphenyl, R2 = Et, X = H (II)] had an EC50 value of 3.8 nmol/L and SI (selectivity index) of up to 25,468 indicating excellent activity against WT HIV-1. In vitro anti-HIV-1 activity and resistance profile studies suggested that compounds (II) and I [R1 = 4-(methylsulfanyl)phenyl, R2 = Et, X = H (III)] displayed potential anti-HIV-1 activity against laboratory adapted strains and primary isolated strains including different subtypes and tropism strains (EC50s range from 4.3 to 63.6 nmol/L and 18.9-219.3 nmol/L, resp.). On the other hand, it was observed that those two compounds (II) and (III) were less effective with EC50 values of 2.77 and 4.87μmol/L for HIV-1A17 (K103N + Y181C). The activity against reverse transcriptase (RT) was also evaluated for those compounds Both (II) and (III) obtained sub-micromolar IC50 values showed their potential in RT inhibition. The pharmacokinetics examination in rats indicated that compound (II) has acceptable pharmacokinetic properties and bioavailability. Preliminary structure-activity relationships and mol. modeling studies were also discussed. In the experiment, the researchers used (3-methyl-1H-pyrazol-5-yl)methanol(cas: 29004-73-7HPLC of Formula: 29004-73-7)

(3-methyl-1H-pyrazol-5-yl)methanol(cas: 29004-73-7) belongs to pyrazoles. Pyrazole derivatives have been reported to exhibit a wide range of applications in medicinal chemistry and pharmacology. A large number of drugs incorporating pyrazole structure have been utilized as partial agonists for nicotinic acid receptors, antidepressants, antimicrobial agents, antiviral agents, and antifungal agents solely or along with the combination of other structural motifs.HPLC of Formula: 29004-73-7

Referemce:
Pyrazole – Wikipedia,
Pyrazoles – an overview | ScienceDirect Topics

《Lewis base-catalyzed intermolecular triazene alkyne cycloaddition for late-stage functionalization and scaffold diversification》 was written by Lv, Shuaipeng; Zhou, Hui; Yu, Xin; Xu, Yue; Zhu, Huijuan; Wang, Min; Liu, Haitao; Dai, Ziru; Sun, Guibo; Gong, Xiaojie; Sun, Xiaobo; Wang, Lei. Category: pyrazoles-derivativesThis research focused ontriazene 3 Trifluoromethylpyrazole cycloaddition Lewis base platelet aggregation inhibitor. The article conveys some information:

3-Trifluoromethylpyrazole and its derivatives are of major interest to both the agrochem. and pharmaceutical industry for their diverse biol. activities. Reported routes for the synthesis of 3-trifluoromethylpyrazoles are hindered by poor regioselectivity and limited scope of application. Here we report a directed Lewis base catalyzed intermol. triazene-alkyne cycloaddition It is featured that the combination of 1,8-diazabicyclo[5.4.0]undec-7-ene and 2,2,2-trifluorodiazoethane produces reactive triazene intermediates, which readily participate in cycloaddition reactions with terminal/internal alkynes, thus assembling densely substituted 3-trifluoromethylpyrazole scaffolds with environmental friendliness and operational simplicity. Synthetic utility of the protocol is highlighted by late-stage functionalization and scaffolds diversification. The practical value is also emphasized in potential platelet aggregation inhibitor synthesis. In addition to this study using 3-(Trifluoromethyl)-1H-pyrazole, there are many other studies that have used 3-(Trifluoromethyl)-1H-pyrazole(cas: 20154-03-4Category: pyrazoles-derivatives) was used in this study.

3-(Trifluoromethyl)-1H-pyrazole(cas: 20154-03-4) belongs to pyrazoles. Pyrazole derivatives have been reported to exhibit a wide range of applications in medicinal chemistry and pharmacology. A large number of drugs incorporating pyrazole structure have been utilized as partial agonists for nicotinic acid receptors, antidepressants, antimicrobial agents, antiviral agents, and antifungal agents solely or along with the combination of other structural motifs.Category: pyrazoles-derivatives

Referemce:
Pyrazole – Wikipedia,
Pyrazoles – an overview | ScienceDirect Topics

Formula: C4H3F3N2In 2015 ,《Ruthenaphosphaalkenyls: synthesis, structures, and their conversion to η2-phosphaalkene complexes》 was published in Organometallics. The article was written by Greenacre, Victoria K.; Trathen, Nicola; Crossley, Ian R.. The article contains the following contents:

The ruthenaphosphaalkenyls [Ru{P:CH(SiMe2R)}Cl(CO)(PPh3)2] (R = Me, Ph, Tol) have been prepared in good yield by the facile hydroruthenation of the resp. phosphaalkynes, RMe2SiCP, with [RuHCl(CO)(PPh3)3]; all three compounds have been structurally characterized in the solid state. Complemented by DFT studies of these, and the precedent [Ru{P:CH(tBu)}Cl(CO)(PPh3)2], the phosphaalkenyl moieties have been established unequivocally to behave as one-electron donors to the coordinately unsaturated, 15-electron “”RuCl(CO)(PPh3)2″” fragment, corroborating an earlier demonstration of nucleophilic character at phosphorus within the tert-Bu system. Notwithstanding, the ruthenaphosphaalkenyls are shown to react with the nucleophiles Lipz’ (pz’ = pz, pz*, pzH,CF3, pzMe,CF3) to afford the η1,η2-chelated pyrazolylphosphaalkene complexes [Ru{η1-N:η2-P,C-P(pz’):CH(R)}(CO)(PPh3)2], which feature a three-membered metallacyclic (Ru-C-P) core. The nature of these novel compounds is discussed, alongside preliminary insight into the process by which they are formed. The results came from multiple reactions, including the reaction of 3-(Trifluoromethyl)-1H-pyrazole(cas: 20154-03-4Formula: C4H3F3N2)

3-(Trifluoromethyl)-1H-pyrazole(cas: 20154-03-4) belongs to pyrazoles. Pyrazole derivatives have been reported to exhibit a wide range of applications in medicinal chemistry and pharmacology. A large number of drugs incorporating pyrazole structure have been utilized as partial agonists for nicotinic acid receptors, antidepressants, antimicrobial agents, antiviral agents, and antifungal agents solely or along with the combination of other structural motifs.Formula: C4H3F3N2

Referemce:
Pyrazole – Wikipedia,
Pyrazoles – an overview | ScienceDirect Topics

In 2012,Gaulier, Steven M.; McKay, Reuben; Swain, Nigel A. published 《A novel three-step synthesis of celecoxib via palladium-catalyzed direct arylation [Erratum to document cited in CA155:562830]》.Tetrahedron Letters published the findings.Category: pyrazoles-derivatives The information in the text is summarized as follows:

On page 6001, Compound 4 in Scheme 1 contained a structure error; the corrected scheme is given. The results came from multiple reactions, including the reaction of 3-(Trifluoromethyl)-1H-pyrazole(cas: 20154-03-4Category: pyrazoles-derivatives)

3-(Trifluoromethyl)-1H-pyrazole(cas: 20154-03-4) belongs to pyrazoles. The application of pyrazole derivatives in the development of anticancer agents has been thoroughly investigated and verified. Moreover, the medicinal features of a number of natural products incorporating pyrazole moiety such as pyrazofurin, pyrazofurin B, pyrazole-3(5)-carboxylic acid and 4-methylpyrazole-3(5)-carboxylic acid have been reported.Category: pyrazoles-derivatives

Referemce:
Pyrazole – Wikipedia,
Pyrazoles – an overview | ScienceDirect Topics

In 1960,Reimlinger, Hans K. published 《Bisdiazoalkanes. II. The preparation of bispyrazolylalkane derivatives》.Chemische Berichte published the findings.Application In Synthesis of Methyl 1H-pyrazole-3-carboxylate The information in the text is summarized as follows:

cf. CA 53, 15060d. Alkynes, activated by α-CO groups, yielded with bisdiazoalkanes in solution or in situ ringsubstituted bispyrazolylalkanes. The reaction of nascent monodiazoalkanes with (CCO2Me)2 (I) gave, depending on the reaction conditions, the expected di-Me pyrazoledicarboxylate (II) together with di-Me bis(dicarbomethoxypyrazolyl)succinate (III) or its alkylated derivatives The III was formed from I with II by a Michael-type addition reaction; the addition which occurred on the pyrazole-N was reversible. HCCCO2Me (IV) yielded in an analogous reaction an acrylic ester derivative, substituted on the pyrazole-N. Na2SO4 (1 g.) and 47 mmoles I in 200 cc. dry Et2O treated at -5° with 1 g. K2CO3, the mixture cooled to -10°, treated dropwise below -5° with stirring with 94 mmoles N,N’-dinitroso-N,N’-diacetylalkylenediamine in 50 cc. absolute MeOH, the mixture stirred 5 hrs. with cooling, filtered, the residue washed with H2O, and recrystallized from hot H2O gave the corresponding bis(4,5-dicarbomethoxy-3-pyrazolyl)alkane (V); the filtrate neutralized with AcOH and evaporated in vacuo gave a dark brown N-free sirup; in this manner were prepared the following V (number of C atoms of alkane chain, m.p., and % yield given): 1, 179-81°, 22; 2 (VI), 199°, 22; 4, 180-1°, 16; 6, 107°, 20; 8, 98-9°, 30. The pentamethylene derivative could only be obtained as a crude brown sirup. VI (2 g.) in 200 cc. 2N H2SO4 refluxed 2 days, cooled, and filtered yielded 1 g. hygroscopic 1,2-bis(4,5-dicarboxy-3-pyrazolyl)ethane (VII), decomposed at 260°. VII (1 g.) added in small portions to excess CH2N2-Et2O, the mixture treated with AcOH, and evaporated yielded 1 g. N,N’-di-Me derivative of VI. [(CH2)4NH2]2 (50 g.) in 200 cc. C6H6 treated dropwise with 40 cc. Ac2O, the mixture stirred 15 min., and filtered gave 76% [AcNH(CH2)4]2 (VIII), m. 130° (Me2CO). VIII in AcOH-Ac2O treated with nitrous gases, poured onto crushed ice, and filtered yielded 96% [AcN(NO)(CH2)4]2 (IX), m. 55-6°. IV (6 g.) in 200 cc. Et2O treated dropwise at 0° with (CH2CH2CHN2)2 in Et2O and filtered after 1 hr. gave 70% 1,4-bis(5-carbomethoxy-3-pyrazolyl)butane, m. 183-4° (H2O). (BzC)2 (10 g.) in 100 cc. Et2O treated in the usual manner with IV yielded 11.8 g. (crude) 1,4-bis(5-benzoyl-3-pyrazolyl)butane, m. 191° (MeOH). I (14.2 g.) and 2 g. Na2SO4 added to 100 cc. Et2O, the mixture cooled to 0°, treated with 2 g. K2CO3 and then during 15 min. with stirring with 10 g. [AcN(N0)CH2]2 (X) in 75 cc. MeOH, and filtered after 2 hrs. yielded 500 mg. 4,4′,5,5-tetracarbomethoxy-3,3′-bipyrazolyl, needles, m. 170° (2:1 C6H6-EtOH). Dry Et2O (100 cc.), 2 g. K2CO3, 2 g. Na2SO4, and 11.3 g. AcN(NO)Me (XI) treated dropwise at 10-15° with 14.2 g. I in 50 cc. MeOH, filtered, and the residue treated with hot H2O left 3.4 g. di-Me α,α’-bis[3,4(4,5)-dicarbomethoxy-1-pyrazolyl]succinate (XII), decomposed at 191°; the Et2O solution evaporated and the residue recrystallized from the aqueous filtrate gave 9 g. di-Me 3,4-dicarbomethoxypyrazole (XIII), m. 141°. A similar run in which MeOH was added to a mixture of I, XI, K2CO3, and Na2SO4 in Et2O yielded 93% XII. A run in which I in MeOH was added to XI, K2CO3, and Na2SO4 in Et2O gave 20% XII and 48% XIII; the XI in MeOH added to I, K2CO3, and Na2SO4 in Et2O gave 74% XII; the I and XI in MeOH added to K2CO3 and Na2SO4 in Et2O yielded 25% XII and 42% XIII. I (2.9 g.) and 3.7 g. XIII in 70 cc. Et2O and 35 cc. MeOH refluxed 4 hrs. and evaporated, the viscous residue heated 1 day on the water bath, diluted with Et2O, filtered, the residue digested with boiling H2O, and filtered left 300 mg. XII. I (4.6 g.) and 4 g. XIII in 50 cc. MeOH and 100 cc. Et2O treated with a few drops concentrated NaOMe in MeOH and filtered after 2 days yielded 4.3 g. XII. XII (5 g.) in 50 cc. MeOH, containing a small piece of Na, neutralized immediately with AcOH, evaporated, the residue treated with petr. ether, filtered, and the filtrate evaporated gave a few drops of oily I; the petr. ether-insoluble solid (1.5 g.) was XIII, m. 141°. XII (3 g.) heated slowly under N to 190°, kept 1 min. at 190°, cooled, treated with boiling H2O, filtered, and the filtrate cooled gave 0.2 g. XIII; 0.2 g. 2nd crop; the H2O-insoluble solid treated with AcOH gave 2.1 g. XII. XII (10 g.) in 200 cc. 2N HNO3 refluxed 2 days, filtered hot, and cooled gave hydrated 3,4-dicarboxypyrazole (XIV), needles, decomposed at 263-4°, which dried 1 day over P2O5 in a desiccator gave XIV.H2O and dried further at 80° over P2O5 gave XIV; the aqueous acidic filtrate extracted 3 days with Et2O, the extract evaporated, and the residue treated with the calculated amount of CH2N2 yielded XIII. XIV and XIII treated with excess CH2N2 yielded the N-Me derivative of XIII, b11 124-5°. XIII (1 g.) in 25 cc. ClCO2Et refluxed 1.5 hrs., evaporated in vacuo, and cooled yielded 77% N-MeO2C derivative of XIII, m. 73° (H2O). I (3.4 g.) and 3.55 g. I. in 50 cc. Et2O treated with a few drops of concentrated NaOMe-MeOH and filtered after standing overnight yielded 0.5 g. di-Me α,α’-di(1-pyrazolyl)succinate (XV), m. 139° (hot H2O). Pyrazole K derivative in dry C6H6 from 5 g. pyrazole treated slowly dropwise with 5 g. (CHClCO2Me)2 in 50 cc. C6H6, the mixture refluxed 0.5 hr., washed with H2O, and worked up yielded 22.4% XV. I (10 g.) and 1 g. Na2SO4 added to 200 cc. dry Et2O, the mixture cooled to -2°, treated with 1 g. K2CO3 and then dropwise during 2.5 hrs. with 6.9 g. X in 130 cc. absolute MeOH, the mixture cooled to -10°, and filtered gave 25% 1-(1,2-dicarbomethoxyvinyl)-4,4′,5,5-tetracarbomethoxy-3,3′-bipyrazolyl, m. 220° (H2O). XI (13 g.) and 14.2 g. I in 50 cc. Et2O treated with 2 g. Na2SO4 and 3 g. K2CO3, the mixture treated dropwise at 15-20° with 25 cc. MeOH, and filtered after 2 hrs. yielded 7 g. di-Me α,α’bis[5(3)-methyl-3,4(4,5)-dicarbomethoxy-1-pyrazolyl] succinate (XVI), decomposed at 143-4°; 0.7 g. 2nd crop; the aqueous filtrate neutralized with AcOH and evaporated, the residue extracted with C6H6, and the oily residue from the extract digested with petr. ether yielded 15% 5(3)-methyl-3,4(4,5)dicarbomethoxypyrazole (XVII), m. 106°, also obtained from I and MeCHN2. AcN(NO)Pr (10 g.) in 50 cc. Et2O treated with 2 g. Na2SO4 and 3 g. K2CO3 and then during 2 hrs. with stirring at 10-15° with 9.7 g. I in 50 cc. MeOH, the mixture filtered after standing overnight, neutralized with AcOH, evaporated in vacuo, and the residue reprecipitated from dioxane with H2O yielded 3.3 g. 5(3)-Et analog of XVI, prisms, decomposed at 123.5° (MeOH); the aqueous dioxane filtrate evaporated and distilled gave 3 g. 5(3)-Et analog of XVII, b0.05 150-2°. AcNHC18H37 in 200 cc. Ac2O-AcOH treated 7 hrs. with nitrous gases and poured onto ice and H2O yielded 94.5% AcN(NO)C18H37 (XVIII), lemon-yellow, m. 43-4° (Me2CO). I (7.1 g.) and 19 g. XVIII in 50 cc. Et2O treated with 1 g. Na2SO4 and 1.5 g. K2CO3 and then during 2 hrs. with 25 cc. MeOH, the mixture filtered after 3 hrs., the residue dissolved in MeOH, and cooled to -40° yielded 64% 1-(N-octadecyldicarbomethoxypyrazolyl)heptadecane, m. 47°. Ba(OH)2 (3 g.) in 50 cc. Et2O and 50 cc. MeOH treated during 2 hrs. with 15.5 g. I and 18 g. AcN(NO)Bu below 25°. the mixture filtered, neutralized with AcOH, evaporated in vacuo, the red-brown viscous residue (21 g.) diluted with Et2O, filtered, evaporated, and the viscous residue (17 g.) fractionated gave 12 g. 5(3)-Pr analog of XVII, b0.0001 140°. I (14.2 g.) and 15 g. AcN(NO)CH2CH2OMe gave in the usual manner 21.5 g. (crude) 5(3)-MeOCH2CH2 analog of XVII, b0.0001 154-6°. IV (8.4 g.) in 100 cc. Et2O and 12 g. XI in 50 cc. MeOH yielded with 2 g. Na2SO4 and 2 g. K2CO3 9.5 g. 3(5)-carbomethoxypyrazole (XIX), m. 142° (MeOH). XI (9.5 g.) in 50 cc. MeOH and 13.3 g. IV in 50 cc. Et2O with 2 g. Na2SO4 and 2 g. K2CO3 gave Me β-(3)-carbomethoxy-1-pyrazolyl]acrylate (XX), m. 110-10.5° (H2O). IV (1.7 g.) and 2.5 g. XIX in 30 cc. MeOH treated with 3 drops concentrated NaOMe-MeOH, the mixture heated 1 hr. on the water bath, and kept 7 days gave 300 mg. XX, m. 110°. After reading the article, we found that the author used Methyl 1H-pyrazole-3-carboxylate(cas: 15366-34-4Application In Synthesis of Methyl 1H-pyrazole-3-carboxylate)

Methyl 1H-pyrazole-3-carboxylate(cas: 15366-34-4) belongs to pyrazoles. The application of pyrazole derivatives in the development of anticancer agents has been thoroughly investigated and verified. Moreover, the medicinal features of a number of natural products incorporating pyrazole moiety such as pyrazofurin, pyrazofurin B, pyrazole-3(5)-carboxylic acid and 4-methylpyrazole-3(5)-carboxylic acid have been reported.Application In Synthesis of Methyl 1H-pyrazole-3-carboxylate

Referemce:
Pyrazole – Wikipedia,
Pyrazoles – an overview | ScienceDirect Topics

The author of 《Monitoring the hydrogen bond net configuration and the dimensionality of aniline and phenyloxamate by adding 1H-pyrazole and isoxazole as substituents for molecular self-recognition》 were Oliveira, Willian X. C.; do Pim, Walace D.; Pinheiro, Carlos B.; Journaux, Yves; Julve, Miguel; Pereira, Cynthia L. M.. And the article was published in CrystEngComm in 2019. Quality Control of 4-(4-Nitrophenyl)-1H-pyrazole The author mentioned the following in the article:

This work describes the synthesis and characterization of a new class of oxamic acid derivatives containing pyrazole and isoxazole as substituents to investigate their ability to form hydrogen bonds aiming at applying them in crystal engineering and mol. self-recognition. In this respect, we report a new synthesis of 2-(4-nitrophenyl)-1,3-propanedial (1) in high yield using SOCl2 as a chlorinating agent. The new oxamic esters 4-(1H-pyrazol-4-yl)phenylene-N-(ethyloxamate) (2d) and 4-(1,2-oxazol-4-yl)phenylene-N-(ethyloxamate) (3d) were prepared from 1. The synthetic route consists of the cyclisation of 1 either with hydrazine to afford 4-(-aminophenyl)-1H-pyrazole (2a) or with hydroxylamine to obtain the isoxazole-based mol. 4-(4-nitrophenyl)-1,2-oxazole (3a). The reduction of 2a and 3a was carried out in an acidic/tin solution to yield 4-(4-ammoniophenyl)-1H-pyrazol-2-ium trichlorostannate(II) chloride monohydrate (2b) and 4-(4-ammoniophenyl)-1,2-oxazole hexachlorostannate(IV) (3b). Basic extraction of 3b provided 4-(4-aminophenyl)-1,2-oxazole (3c). The reduction of 2a to 4-(4-aminophenyl)-1H-pyrazole (2c) was achieved by means of hydrazine associated with supported palladium on carbon. The condensation of 2c and 3c with Et chlorooxoacetate delivers oxamic esters 2d and 3d. In n-tetrabutylammonium hydroxide solution 2d is fully hydrolyzed, obtaining the n-tetrabutylammonium salt of 4-(1H-pyrazole-4-yl)phenylene-N-oxamate as a hemihydrate (2e). The low stability of isoxazole mols. in basic solutions was proved by crystallizing the n-tetrabutylammonium salt of 1-cyano-1-(4-nitrophenyl)-2-oxoethanide (3f) (obtained by cleavage of 3d with n-Bu4NOH) and preparing its conjugated acid 2-(4-nitrophenyl-3-oxopropanenitrile) (3e). The structures of 2b, 3b, 3d and 2e were solved by single crystal X-ray diffraction techniques. The anal. of their crystal packing reveals hydrogen bond features compatible for all compounds as well as some differences depending on the pH of the crystallization solution and the presence or absence of the oxamate group due to the increase of hydrogen bond donors and acceptors. In the experimental materials used by the author, we found 4-(4-Nitrophenyl)-1H-pyrazole(cas: 114474-26-9Quality Control of 4-(4-Nitrophenyl)-1H-pyrazole)

4-(4-Nitrophenyl)-1H-pyrazole(cas: 114474-26-9) belongs to pyrazoles. Pyrazoles are commonly used scaffold molecules in drug discovery projects. The use of pyrazole derivatives is based on their analgesic, neuroleptic, anticonvulsant, monoamine oxidase inhibitory, anti-inflammatory, antipyretic, antiarrhythmic, sedative, muscle relaxant, antidiabetic and antibacterial activities. Quality Control of 4-(4-Nitrophenyl)-1H-pyrazole

Referemce:
Pyrazole – Wikipedia,
Pyrazoles – an overview | ScienceDirect Topics

《Synthesis and solid-state structure of thermally stable linear bi-pyrazoles》 was written by Maspero, Angelo; Cernuto, Giuseppe; Galli, Simona; Palmisano, Giovanni; Tollari, Stefano; Masciocchi, Norberto. Electric Literature of C9H7N3O2 And the article was included in Solid State Sciences on August 31 ,2013. The article conveys some information:

The long and rigid bi-pyrazolyl-based ligands 2,6-bis[4-(1H-pyrazol-4-yl)phenyl]pyrrolo[3,4-f]isoindole-1,3,5,7(2H,6H)-tetrone, , and 2,5-bis[4-(1H-pyrazol-4-yl)phenyl]thiazolo[5,4-d]thiazole, were isolated in pure form, with satisfying yields, as very insoluble polycrystalline materials. Their thermal behavior was studied by coupling thermal analyses and variable-temperature x-ray powder diffraction measurements. Their crystal structures were unraveled from powder diffraction data by a rather unconventional structure determination approach, without the a priori knowledge of the unit cell parameters. Inline with shorter analogs, successfully employed in the formation of porous MOFs with intriguing functional properties, 2,6-bis[4-(1H-pyrazol-4-yl)phenyl]pyrrolo[3,4-f]isoindole-1,3,5,7(2H,6H)-tetrone and 2,5-bis[4-(1H-pyrazol-4-yl)phenyl]thiazolo[5,4-d]thiazole are promising to construct higher-porosity materials, potentially capable of hosting nano-sized guests.4-(4-Nitrophenyl)-1H-pyrazole(cas: 114474-26-9Electric Literature of C9H7N3O2) was used in this study.

4-(4-Nitrophenyl)-1H-pyrazole(cas: 114474-26-9) belongs to pyrazoles. Pyrazoles are commonly used scaffold molecules in drug discovery projects. The use of pyrazole derivatives is based on their analgesic, antipyretic, neuroleptic, anticonvulsant, antiarrhythmic, sedative, muscle relaxant, monoamine oxidase inhibitory, anti-inflammatory, antidiabetic and antibacterial activities. Electric Literature of C9H7N3O2

Referemce:
Pyrazole – Wikipedia,
Pyrazoles – an overview | ScienceDirect Topics

Formula: C5H6N2O2In 1976 ,《Modified nucleosides. V. Synthesis of pyrazole nucleosides》 appeared in Zhurnal Obshchei Khimii. The author of the article were Akhrem, A. A.; Garbuz, N. I.; Kvasyuk, E. I.; Mikhailopulo, I. A.. The article conveys some information:

Pyrazole nucleosides I, II (R = Ac, R1 = OEt) were obtained in 52 and 26% yields by treatment of Et acetoxymethylpyrazolecarboxylate with α-D-glucopyranose pentaacetate. Subsequent aminolysis yielded 90% I, II (R = H, R1 = NH2). Analogously obtained were 71 and 11% III, IV (R = Bz, R1 = Ac, R2 = OEt) which were treated with NH3 to give 90% III, IV (R = R1 = H, R2 = NH2). Similar results were obtained by glucosylation of Me pyrazolecarboxylate and by ribosylation of Et 4-acetoxymethyl-3-pyrazolecarboxylate. The experimental part of the paper was very detailed, including the reaction process of Methyl 1H-pyrazole-3-carboxylate(cas: 15366-34-4Formula: C5H6N2O2)

Methyl 1H-pyrazole-3-carboxylate(cas: 15366-34-4) belongs to pyrazoles. Pyrazole derivatives have been reported to exhibit a wide range of applications in medicinal chemistry and pharmacology. A large number of drugs incorporating pyrazole structure have been utilized as partial agonists for nicotinic acid receptors, antidepressants, antimicrobial agents, antiviral agents, and antifungal agents solely or along with the combination of other structural motifs.Formula: C5H6N2O2

Referemce:
Pyrazole – Wikipedia,
Pyrazoles – an overview | ScienceDirect Topics

Computed Properties of C5H6N2O2In 2004 ,《Synthesis and luminescence properties of lanthanide(III) chelates with polyacid derivatives of thienyl-substituted terpyridine analogues》 was published in Journal of Luminescence. The article was written by Yuan, Jingli; Tan, Mingqian; Wang, Guilan. The article contains the following contents:

Two new polyacid derivative ligands of thienyl-substituted terpyridine analogs, N,N,N1,N1-[4′-(2”’-thienyl)-2,2′:6′,2”-terpyridine-6,6”-diyl]bis(methylenenitrilo) tetrakis(acetic acid) (TTTA) and N,N,N1,N1-[2,6-bis(3′-aminomethyl-1′-pyrazolyl)-4-(2”-thienyl)pyridine]tetrakis(acetic acid) (BTTA), were synthesized, and the luminescence properties of their Eu3+ and Tb3+ chelates were studied. The Eu3+chelates of the two ligands are strongly luminescent having luminescence quantum yields of 0.150 (TTTA-Eu3+) and 0.114 (BTTA-Eu3+), and lifetimes of 1.284 ms (TTTA-Eu3+) and 1.352 ms (BTTA-Eu3+), whereas their Tb3+ chelates are weakly luminescent. The TTTA-Eu3+ chelate was used for streptavidin (SA) labeling, and the labeled SA was used for time-resolved fluoroimmunoassay of insulin in human sera. The method gives the detection limits of 33 pg ml-1. In the part of experimental materials, we found many familiar compounds, such as Methyl 1H-pyrazole-3-carboxylate(cas: 15366-34-4Computed Properties of C5H6N2O2)

Methyl 1H-pyrazole-3-carboxylate(cas: 15366-34-4) belongs to pyrazoles. Pyrazole derivatives have been reported to exhibit a wide range of applications in medicinal chemistry and pharmacology. A large number of drugs incorporating pyrazole structure have been utilized as partial agonists for nicotinic acid receptors, antidepressants, antimicrobial agents, antiviral agents, and antifungal agents solely or along with the combination of other structural motifs.Computed Properties of C5H6N2O2

Referemce:
Pyrazole – Wikipedia,
Pyrazoles – an overview | ScienceDirect Topics